Abstract: Embodiments herein relate to a system (200; 300; 400; 500) for obtaining methanol from foul condensate (101) of a pulping process. The system (200; 300; 400; 500) comprises a primary stripper (102) arranged to strip the foul condensate (101) from pollutants, whereby a first methanol-containing condensate is obtained from the polluted stripper off gases (SOGs). The system (200; 300; 400; 500) also comprises a first acidification unit (202) arranged to acidify the first methanol-containing condensate. Further, the system (200; 300; 400; 500) comprises a secondary stripper (204) arranged to strip the acidified first methanol-containing condensate from pollutants to obtain a second methanol-containing condensate, and a distillation column (107) arranged to distil the second methanol-containing condensate from the secondary stripper (204) so as to obtain methanol.

Abstract: Embodiments herein relate to a system (200; 300; 400; 500) for obtaining methanol from foul condensate (101) of a pulping process. The system (200; 300; 400; 500) comprises a primary stripper (102) arranged to strip the foul condensate (101) from pollutants, whereby a first methanol-containing condensate is obtained from the polluted stripper off gases (SOGs). The system (200; 300; 400; 500) also comprises a first acidification unit (202) arranged to acidify the first methanol-containing condensate. Further, the system (200; 300; 400; 500) comprises a secondary stripper (204) arranged to strip the acidified first methanol-containing condensate from pollutants to obtain a second methanol-containing condensate, and a distillation column (107) arranged to distil the second methanol-containing condensate from the secondary stripper (204) so as to obtain methanol.

Abstract: An engine and transmission spacer with integrated hydraulic tank preferably includes a spacer case, an engine flange and a transmission flange. The spacer case includes an outer peripheral wall, a first outer wall and a second outer wall. The first outer wall is formed on one end of the outer peripheral wall and the second outer wall is formed on an opposing end of the outer peripheral wall. The engine flange extends from one end of the spacer case and the transmission flange extends from the opposing end thereof. A fluid cavity is formed in an inner surface of the outer peripheral wall, the first outer wall and the second outer wall. At least one pump port is preferably formed through a side of the outer peripheral wall. An oil pump is used to transfer fluid from the fluid cavity to another location.

Abstract: A respirator apparatus includes a respirator body, a filter cartridge receiver integral with and extending from the respirator body, and a filter cartridge. The filter cartridge includes a nozzle element being integral with the filter cartridge. The respirator body and filter cartridge are configured to be fluidically coupled through sleeve-fit engagement between the filter cartridge receiver and nozzle element and the filter cartridge receiver and nozzle element define an airflow channel.

Abstract: The present invention relates to a method for production of p-cymene from cyclic monoterpenes in the presence of an Fe(III)-salt as a catalyst. In particular it relates to a method for production of p-cymene from cyclic monoterpenes containing high levels of sulphur, such as crude sulphate turpentine. The method can be performed as two different, subsequent processes for the isomerization and oxidation reactions, or in a single process wherein these reactions take place at the same time.

Abstract: In one embodiment, a method for manufacturing a fluid storage tank assembly for an off-road vehicle includes disposing a support ring within a cavity of a rotational mold, in which the cavity is shaped to form a fill spout of the fluid storage tank assembly. The method further includes flowing a liquid polymeric material within the rotational mold such that the liquid polymeric material enters the cavity, directly contacts the support ring, and bonds to the support ring as the liquid polymeric material hardens.

Abstract: The invention relates to a method of isolating cymene comprising the following steps: a) providing a solution comprising cymene and monoterpenes, b) adding sulphuric acid to the solution in a) such that the concentration of sulphuric acid in the solution is at least 0.5% (w/w), such as 1-25% (w/w), c) distilling the solution mixture from step b) such that a target chemical stream enriched in cymene is obtained and separated from a residual stream.

Abstract: A method of detecting a change in hearing of a user includes providing a sound generating device for providing both a content audio signal and a hearing test audio signal. The sound generating device is used to provide hearing test audio sounds of different loudnesses around a threshold of hearing of the user. None of these sounds is calibrated to a pre-specified decibel level. A first threshold of hearing is determined at a first time and a second threshold of hearing is determined at a second time. The first threshold of hearing is compared with the second threshold of hearing.

Abstract: The present invention relates to Acetyl Coenzyme A Carboxylase (ACC) inhibitors according to formula (I), or an enantiomer thereof, or a pharmaceutically acceptable salt thereof, where R1, R2, R3, R4, R5, E, L, Z and n are as defined herein, to processes for preparing such compounds, to pharmaceutical compositions containing them, to the use of such inhibitors and to methods for their therapeutic use, particularly in the treatments of obesity and diabetes mellitus.

Abstract: The present invention relates to compounds of formula (I) wherein variable groups are as defined within; pharmaceutically acceptable salts, solvates, solvates of such salts and prodrugs thereof and their use as ileal bile acid transport (IBAT) inhibitors for the treatment of hyperlipidaemia.

Abstract: The present invention relates to compounds of formula (I), wherein variable groups are as defined within; pharmaceutically acceptable salts, solvates, solvates of such salts and prodrugs thereof and their use as ileal bile acid transport (IBAT) inhibitors for the treatment of hyperlipidaemia.

Abstract: The present invention relates to compounds of the formula (I): (wherein variable groups are as defined within) pharmaceutically acceptable salts, solvates, solvates of such salts and prodrugs thereof and their use as ileal bile acid transport (IBAT) inhibitors for the treatment of hyperlipidaemia.

Abstract: The present invention relates to compounds of formula (I) wherein Rv, R1, R2, Rx, Ry, M, Rz, v, R3, R4, R5 and R6 are as defined within; pharmaceutically acceptable salts, solvates, solvates of such salts and prodrugs thereof and their use as ileal bile acid transport (IBAT) inhibitors for the treatment of hyperlipidaemia. Processes for their manufacture and pharmaceutical compositions containing them are also described.

Abstract: The present invention relates to compounds of formula (I): wherein variable groups are as defined within; pharmaceutically acceptable salts, solvates, solvates of such salts and prodrugs thereof and their use as ileal bile acid transport (IBAT) inhibitors for the treatment of hyperlipidemia.

Abstract: The present invention relates to compounds of formula (I) wherein R1 and R2 are independently selected from C1-6alkyl; one of R4 and R5 is a group of formula (IA): R3, R6, R7, R8, R9, R10 and R11 and the other of R4 and R5 are as defined within, pharmaceutically acceptable salts, solvates, solvates of such salts and prodrugs thereof and there use as ileal bile acid transport (IBAT) inhibitors for the treatment of hyperlipidaemia. Processes for their manufacture and pharmaceutical compositions containing them are also described.

Abstract: The present invention relates to compounds of formula (I) wherein variable groups are as defined within; pharmaceutically acceptable salts, solvates, solvates of such salts and prodrugs thereof and their use as ileal bile acid transport (IBAT) inhibitors for the treatment of hyperlipidaemia. Processes for their manufacture and pharmaceutical compositions containing them are also described.

Abstract: The present invention relates to compounds of formula (I) wherein Rv, R1, R2, Rx, Ry, M, Rz, v, R3, R4, R5 and R6 are as defined within; pharmaceutically acceptable salts, solvates, solvates of such salts and prodrugs thereof and their use as ileal bile acid transport (IBAT) inhibitors for the treatment of hyperlipidaemia. Processes for their manufacture and pharmaceutical compositions containing them are also described.

Abstract: The present invention relates to compounds of formula (I): wherein variable groups are as defined within; pharmaceutically acceptable salts, solvates, solvates of such salts and prodrugs thereof and their use as ileal bile acid transport (IBAT) inhibitors for the treatment of hyperlipidaemia. Processes for their manufacture and pharmaceutical compositions containing them are also described.

Abstract: The present invention relates to compounds of formula (I), wherein variable groups are as defined within; pharmaceutically acceptable salts, solvates, solvates of such salts and prodrugs thereof and their use as ileal bile acid transport (IBAT) inhibitors for the treatment of hyperlipidaemia. Processes for their manufacture and pharmaceutical compositions containing them are also described.

Abstract: The present invention relates to compounds of the formula (I): (wherein variable groups are as defined within) pharmaceutically acceptable salts, solvates, solvates of such salts and prodrugs thereof and their use as ileal bile acid transport (IBAT) inhibitors for the treatment of hyperlipidaemia. Processes for their manufacture and pharmaceutical compositions containing them are also described.